A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation
CONCLUSIONS: Prophylactic use of oral acyclovir effectively reduced the incidence of CIOM in patients with HM who were undergoing AHSCT.TRIAL REGISTRATIONS: This trial was registered at the Clinical Research Information Service in the Republic of Korea under the number KCT0003885 (registration date 03/05/2019).PMID:38102638 | DOI:10.1186/s12903-023-03623-6
Source: Cancer Control - Category: Cancer & Oncology Authors: Junshik Hong Hee-Kyung Park Sung-Ho Chang Ja Min Byun Dong-Yeop Shin Youngil Koh Sung-Soo Yoon Youngnim Choi Inho Kim Source Type: research
More News: Acyclovir | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Oral Cancer | Stem Cell Therapy | Stem Cells | Study | Transplants | Zovirax